Reporting an adverse event

Cycle Pharma is committed to protecting the safety of patients who receive our products.

Adverse events

Continuous monitoring of the safety of a drug throughout the duration of its use helps to ensure that its risks and benefits remain acceptable.

If you have experienced an adverse event or think you may be experiencing an adverse event, you should seek advice from a healthcare professional.

An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g. nausea, chest pain), signs (e.g. tachycardia, enlarged liver) or the abnormal results of an investigation (e.g., laboratory findings, electrocardiogram).

All adverse events should be reported to Cycle Pharmaceuticals by:

TASCENSO ODT (fingolimod)

Phone
+1-888-533-1625 (toll-free USA)

Email
drugsafety@cyclepharma.com

 

All other products

Phone
+1-855-831-5413 (toll-free USA and Canada)
+0-808-196-5696 (toll-free UK)

Email
drugsafety@cyclepharma.com

 

Cycle Pharma Logo Light

CYCLE Pharmaceuticals Limited is registered in England and Wales. Registration number 07933058.

Modern Slavery Statement
Head Office (UK)

Cycle Pharmaceuticals Ltd
The Broers Building
21 JJ Thomson Ave
Cambridge, CB3 0FA
United Kingdom

+44 1223 354118

US Office

Cycle Pharmaceuticals Inc.
19 Clifford St
Detroit, MI 48226
United States

+1 800 903 1793

US Office

Cycle Pharmaceuticals Inc.
200 Portland St
Boston, MA 02114
United States

+1 800 903 1793

© 2026 Cycle Pharmaceuticals Limited. All rights reserved.

GL-CC-2500026 | June 2025
Follow us